|
GB0712524D0
|
|
Novel schizophrenia associated genes
|
|
WO2007145308A1
|
|
Agent for prevention and/or treatment of glomerulopathy
|
|
WO2007126043A1
|
|
Use as drugs of carboxylic acid derivatives having thiazole rings
|
|
TW200811083A
|
|
2-aminobutanol compounds and their medical use
|
|
JP2007308484A
|
|
Medicine for preventing and/or treating hyperlipidemia
|
|
KR20070102953A
|
|
Medicine for prevention and/or treatment of hyperlipidemia
|
|
TW200813015A
|
|
2-(cyclic amino)-pyrimidone derivatives
|
|
JP2007252372A
|
|
Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition and diagnostic reagent
|
|
JP2007246518A
|
|
Crystal of cyclopropenone compound
|
|
JP2007238609A
|
|
Pharmaceutical for preventing ischemic disease in diabetic
|
|
KR20070081767A
|
|
A medicine for preventing ischemic disease in a diabetic patient
|
|
JP2007084579A
|
|
Heparin solution-including pre-filled syringe preparation and method for producing the same
|
|
JP2007130025A
|
|
Process for purifying human serum albumin derived from gene manipulation
|
|
WO2007055374A1
|
|
Therapeutic agent for osteoporosis
|
|
WO2007055312A1
|
|
Plastic container filled with aqueous solution containing pyrazolone compound
|
|
WO2007049731A1
|
|
Novel cell membrane-permeable peptide
|
|
WO2007049587A1
|
|
Enteric-coated preparation
|
|
JP2007008957A
|
|
Benzene compound and pharmaceutical use thereof
|
|
JP2007056011A
|
|
Miniaturized orally administrable preparation of sarpogrelate hydrochloride
|
|
KR20070015046A
|
|
Minimized oral dosage formulation of sarpogrelate hcl
|
